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Introduction
Alzheimer's disease (AD) is neuropathologically characterized by senile plaques containing -amyloid peptides (A), as well as neurofibrillary tangles consisting of hyperphosphorylated tau. The amyloidogenic Aβ peptide is proteolytically derived from the amyloid precursor protein (APP) by distinct enzymatic activities known as β-secretase (or BACE) and -secretase (4, 5) . Overproduction or impaired Aβ clearance can both lead to Aβ accumulation. Recent evidence indicates that late-onset AD cases are likely caused by an overall impairment in Aβ clearance (6) .
Synaptojanin 1 (synj1), a major negative regulator of the levels of PI(4,5)P 2 in the nervous tissue, has been implicated in the regulation of endocytic traffic at synapses (1) . Trisomy of synj1 in Down syndrome mouse models causes a deficiency in PI(4,5)P 2 as well as learning deficits (7) , while synj1 haploinsufficiency is protective against Aβ induced neurotoxicity in mouse models of AD (2, 3) . In the current study, we link synj1 to regulation of cellular Aβ clearance.
We have found that down-regulation of synj1 leads to reduced Aβ accumulation and amyloid plaque load. Synj1 knockdown promotes Aβ uptake and lysosomal trafficking, thereby facilitates cellular Aβ clearance without affecting BACE or -secretase expression levels or enzymatic activities to generate Aβ. These effects are dependent on PI(4,5)P 2 that increases with synj1 down-regulation. As a consequence, reduction of synj1 attenuates amyloid induced neuropathologic changes and behavior deficits in an AD transgenic mouse model. Our findings uncover a novel regulatory mechanism by a PI(4,5)P 2 degrading enzyme synj1 that controls cellular Aβ degradation through the endosomal/lysosomal pathway.
Experimental Procedures

Antibodies and Reagents
The following antibodies were used: 4G8 and 6E10 (Covance), anti-synj1 (mouse AC1, Novus), anti-amyloid (AB2454, Cell Signaling), anti-cleaved Notch1 Val1744 (D3B8, Cell Signaling), anti-BACE1 C-terminus MAB5308 (clone 61, Millipore), anti-flag (Sigma), antiRab5 and anti-β actin (Santa Cruz), anti-LAMP1 (Abcam), anti-mouse, anti-rabbit, and anti-goat HRP conjugates (Vector Laboratories), TexasRed conjugated anti-mouse IgG (Vector Laboratories Inc.). pAb369 (C-terminal APP antibody) was used to detect human and mouse holo-APP and C-terminal fragments (8) . The amyloid specific luminescent conjugated oligothiophene (LCO) was used for histological staining of the presence of amyloid deposits in combination with immunofluorescence (9) . AB14 (N-terminal PS1 antibody) (10) was used to detect PS1. Fluoro-conjugated Aβ 42 555 and Aβ 42 488 were purchased from AnaSpec (Fremont, CA). Aβ peptides were pretreated with trifluoroacetic acid that was distilled under nitrogen, washed with 1,1,1,3,3,3-hexafluoro-2-propanol, stored at -20 °C, and dissolved in DMSO to 200μM before use. Aβ 42 solution was centrifuged at 17,000 × g for 30 seconds to remove aggregated Aβ. The lysosomal inhibitors Leupeptin, Pepstatin A and E-64d were purchased from Sigma (St. Louis, MO). A PIP 2 modulator m-3m3FBS which can activate PLC and deplete PIP 2 in cells, and its inactive analog o-3m3FBS (11) were purchased from Santa Cruz Biotechnology Inc.
Cell Lines
Mouse N2a neuroblastoma cells stably transfected with cDNAs encoding human Swedish mutant APP were maintained in medium containing 50% DMEM, 50% OPTI-MEM, supplemented with 5% fetal bovine serum, antibiotics and 200 mg/ml G418 (Invitrogen). N2a cells were transfected with synj1siRNA and maintained for 4-5 days to achieve about 50-80% knockdown of synj1 protein levels. Alternatively, cells were treated with a -secretase inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine tbutyl ester (DAPT) (12, 13) at 2µM overnight before subject for further analysis. In some experiments, cells after siRNA treatment were incubated with a PIP 2 modulator (m-3-FBS or an inactive analog o-3-FBS) at 6.25μM overnight before subjected for further analysis.
siRNA Oligonucleotides
To knock down synj1 protein expression, three siRNA duplexes specifically targeting synj1 (IDT Inc.) were synthesized. Sequences of the syn1siRNAs are as follows: siRNA1 forward 5′-GUC UGG UUC UUG AAC GCU AUG CUG CGG-3′; reverse, 5′-GCA GCA UAG CGU UCA AGA ACC AGAC-3′. siRNA2 forward GGA CUU CAC GGA AAG AUA AUU AAGT-3'; reverse 5'-ACU UAA UUA UCU UUC CGU GAA GUC CAA-3'; siRNA3 forward 5'-AGC ACG GAA AGA UAA UAU AGG GCGT-3'; reverse 5'-ACG CCC UAU AUU AUC UUU CCG UGC UGU-3'; a scrambled universal Negative Control RNA Duplex was used as a negative control (NC1, IDT Inc.).
Cell Transfection
For siRNA analysis, N2a cells were seeded at 50% to 60% confluence and transfected with 200 pmol synj1 siRNA duplex versus control duplex (per well of a six-well plate) using Lipofectamine RNAimax (Invitrogen) according to the manufacturer's instructions.
Cell Lysate Analysis
After transfection, cells were harvested in lysis buffer (14) . Equal amounts of total protein were loaded onto 10-20% Tricine SDS-PAGE gels for electrophoresis and transferred to PVDF membranes. The membranes were analyzed by Western blot using 6E10 to detect holoAPP and βCTF/C99. Aβ 40 and Aβ 42 levels in media were determined by human ELISA kits (WAKO), according to the manufacturer's instructions. In some experiments, the amount of Aβ in media and lysate with synj1 or control siRNA treatment were determined in the presence of lysosomal inhibitors (Pepstatin A: 10 μM, Leupeptin: 100 μM, E-64d: 50 μM) to block lysosomal degradation of Aβ. Alternatively, a PIP 2 modulator m-3m3FBS or its inactive analog o-3m3FBS was added with or without lysosomal inhibitors to determine whether the degradation of Aβ with synj1 reduction is dependent upon elevated PIP 2 levels.
Immunoprecipitation.
Lysates were diluted with immunoprecipitation (IP) buffer (10) , and immunoprecipitated using antibody 4G8 followed by immunoblotted with 6E10 for detection of intracellular Aβ and βCTF. Media were immunoprecipitated using 4G8 antibodies (Covance) and immunoblotted with 6E10 for detection of media Aβ as described before (15) . In some experiments, after siRNA transfection, N2a cells were treated with DMSO lysosomal inhibitors, or PIP 2 modulators overnight before analysis of media and lysate Aβ production.
Generation of synj1 Haploinsufficient Mice with AD Transgenic Mouse Background
Human Swedish APP and FAD-linked PS1 E9 mutant transgenic mice (16, 17) were mated with heterozygous synj1 null mice (synj1 +/-) (1). Double heterozygous F1s were then bred with heterozygous synj1 null mice only to generate offspring that express human Swedish mutant APP and FAD-linked PS1 E9 in the synj1 +/-background. Genotypes were determined by PCR amplification as described (1, 16, 17) .
Brain Lysate Preparation and Analysis
Mouse brains were rapidly removed, hemisected, and snap frozen before further analysis. Each frozen hemi-brain was then processed via step-wise solubilization (14, 18) . Lysates of hemi brains derived from APP/PS1 +/-synj1 +/+ or APP/PS1 +/-synj1 +/-at 9-month of age were analyzed by SDS-PAGE and immunoblotted with 6E10 to determine levels of holoAPP and βCTF/C99. Levels of Aβ 40 and Aβ 42 were determined by human Aβ 40 and highsensitivity human Aβ 42 ELISA kits (Wako), according to the manufacturer's instructions. Results were normalized to wet brain weight.
Immunohistochemistry and LCO Staining of Amyloid Plaque
The hemi-brains of 9-month old APP/PS1 +/-synj1 +/+ or APP/PS1 +/-synj1 +/-mice were processed, embedded and sectioned at 10µm. For amyloid plaque quantitation, the blocks were serial sectioned across the whole hippocampal regions and every 8 sections were used for staining (~20 sections/animal). After deparaffination and antigen retrieval process, the brain sections were treated with anti-amyloid antibody AB2454 or 6E10 (1:200 dilution in TBS buffer) overnight at 4 0 C. Following a thorough rinse in TBS buffer, the sections were incubated with secondary antibodies, i.e., biotinylated goat anti-mouse IgG or biotinylated goat anti-rabbit IgG (diluted 1:200 in TBS buffer), and then incubated with avidin biotinylated enzyme complex and DAB. The amyloid plaque load density in the hippocampal region, as well as CA1/3 and dentate gyrus subregions, was measured using Sinq Image Analysis System (Sinq Inc.) (19, 20) . Alternatively, the brain sections were stained with anti-amyloid antibodies followed by incubated with secondary antibody Texas-red conjugated anti-rabbit or anti-mouse IgG as well as LCO reagent (21) for double staining of amyloid before confocal microscopy analysis (LSM510, Zeiss).
Novel Object Recognition Task
Human Swedish APP and FAD-linked PS1mutant transgenic mice show a deficit in the novel object recognition (NOR) memory task (22) . Littermates at 4-5 months of age were tested in NOR, with onset of the exploration time defined as the moment the head of the animal approached the object within a 2cm radius. Briefly, animals were habituated to testing arena for 10min on day1. After 24 hours, animals were tested with two trials (identical objects for 10 min followed by one novel/one familiar object for 4 min). The inter trial interval was 1h. Each animal was videotaped from overhead cameras and scored for total time spent investigating objects per trial. The objects were randomized left and right, as well as between animals. They were cleaned with alcohol between trials/animals to prevent odor cues.
Spatial Alternation/Y-Maze Task
Briefly the Y-maze test was performed in a Yshaped maze with three white opaque plastic arms at a 120 0 angle from each other (23, 24) . The test involves animals freely explored the three arms of Y maze for 8 min ( Figure 3B ). Appropriate external cues were assigned for each arm. All animal activities were recorded by video camera and the number of arm entries and the number of triads were determined to calculate the percentage of alternation. An entry occurs when all four limbs are within the arm.
In Vitro -secretase Assays
In vitro -secretase assays using the recombinant C100-flag (kindly provided by Yue-Ming Li at Memorial Sloan Kettering Cancer Center) or N100-flag substrates (1696MYVAAAAFVLLF FVGCGVLLSRKRRRQGQLWFPEGFKVSEA SKKKRREPLGEDSVGKPLKNASDGALMDD NQNEWGDEDLE-1777-DYKDDDDK-STOP). The membranes containing -secretase were prepared from N2a cells without overexpressing any transgene and solubilized in 2% CHAPSO. Incubation of -secretase membranes and substrates C100flag or N100flag, for 90 min were performed as previously reported (25, 26) .
Aβ Uptake Assay
N2a Swedish mutant APP cells were transfected with synj1 siRNA or control siRNA duplex as indicated. At 4 day post transfection, cells were incubated with biotin-conjugated Aβ 42 in PBS for 1 hour at 37 0 C as described previously (27, 28) . Cells were subsequently washed by ice cold PBS 5 times followed by incubated with 100µM glutathione for 15 min at 4 0 C. Cells were washed another two times with PBS and then incubated with 5mg/ml iodoacetamide for 15 min followed by washing with ice cold PBS 5 times before being harvested in 1xRIPA buffer as described . Lysates were subsequently immunoprecipitated by streptavidin beads, analyzed by SDS PAGE and western blotting with 6E10 for internalized biotin-Aβ 42 .
Similar experiments were performed in primary neuron culture derived from embryonic day 17 old synj1 +/+ versus synj1 -/-animals. In some experiments, cells after siRNA treatment were incubated with a PIP 2 modulator (m-3-FBS or an inactive analog o-3-FBS) at 6.25μM overnight before subjected for Aβ uptake assay.
Cellular Aβ Turnover Rate Assay
For a time course of Aβ degradation, N2a Swedish mutant APP cells were transfected with synj1 siRNA or control siRNA duplex as indicated. At 4 day post transfection, cells were divided into six-well plates coated with 100 g/ml polyornithine and allowed to recover for 5 hours. Cells were subsequently treated with 50g/ml cycloheximide (CHX) in serum-free and antibiotic-free DMEM (29) . At the indicated time points, cells were washed in ice cold PBS and then harvested in RIPA buffer as described (14) . Lysates were subsequently analyzed by SDS PAGE and western blotting with 6E10 for Aβ and holoAPP.
Neuronal Culture and Confocal Microscopy
Primary hippocampal neurons were obtained from 17-day-old embryos of synj1 +/+ , synj1
+/-and synj1 -/-mice, and grown in Neurobasal medium (Gibco) supplemented with 0.5 mM Glutamax (Gibco), 2% B27 (Gibco), and 1% Penicillin-Streptomycin (Invitrogen), in dishes containing poly-D-lysine coated cover glasses (Nalge Nunc International, Rochester, NY) for 7 days in vitro. They were then incubated with Alexa-Aβ 555 or Alexa-Aβ 488 for various time periods before fixation and double-stained for endosomal and lysosomal markers Rab5 and LAMP1 as well as a nuclear marker DAPI (blue) before confocal fluorescence microscopy analysis (Zeiss, Germany). Similar experiments were performed in N2a cells after control or synj1 siRNA transfection, followed by incubation with Alexa-Aβ 555 or Alexa-Aβ 488 . Fluorescent colocalization analysis was quantified using Zen program to calculate colocalized pixels (subtracted by background) and colocalization coeffiency as previously described (30,31). Data are presented as % of control ± SEM.
Statistical Analysis
Densitometric analysis of western blot bands (integrated density) was performed using Multigauge v3.1 software (Fujifilm). Levels of holoAPP, βCTF/C99, Aβ, synj1, BACE1, PS1, biotin-Aβ, C100-/N100-flag were normalized to actin levels and expressed as percentage of control. Absolute Aβ 40 and Aβ 42 concentrations were quantitatively determined by sandwich ELISA (Wako) and expressed as percentage of control. For all analysis, independent-samples t tests (parametric design) were used to determine significant mean differences (the threshold for significance is set at p<0.05). Where two or more variables were compared, a one-way ANOVA with post-hoc tests were used to test group differences for multiple comparisons. All statistical analysis was performed using SPSS v21.0.
Results
Knockdown of Synaptojanin 1 (synj1) Reduces Aβ in N2a Swedish Mutant APP Cells-
We first analyzed the effects of synj1 knockdown on Aβ levels in N2a cells stably expressing human Swedish mutant APP. Transfection with siRNA reduced synj1 protein levels by 50-80% after 4-5 days ( Fig. 1A and B). Under these conditions, both extracellular and intracellular A levels were significantly decreased by 31.8%±11.0% and 53.5%±9.88% respectively, compared to control siRNA transfection (Fig.1B, (16, 17) , were generated and amyloid plaque burden, as well as Aβ 40 and Aβ 42 levels in the brains of 9-month old mice were analyzed. As shown in Fig. 2A , amyloid plaque load in hippocampus was determined by both immunoperoxidase (left panels) and immunofluorescence (right panels). There was an obvious reduction in the amount of densecore plaques (doubled stained by LCO and antiamyloid antibody AB2454). The stereological quantitation of amyloid plaques in 9-month old APP/PS1 +/-synj1 +/-male mouse brains showed that total plaque load in hippocampus, as well as in dentate gyrus subregions, was reduced by 34 (11) . Since PI(4,5)P 2 is a major substrate for synj1 and knockdown of synj1 elevates brain PI(4,5)P 2 levels ((1,2) and Figure 3C ), we next investigated whether down-regulation of synj1 affected -secretase processing of APP.
Utilizing a well-established in vitro -secretase assay (25, 26) , we characterized the activity of solubilized -secretase derived from membrane fractions of N2a wild-type cells transfected with synj1 siRNA or control siRNA toward the substrates C100-Flag (Fig. 5A ) and N100-Flag (Fig. 5B) . Synj1 knockdown did not affect -secretase cleavage of C100 to generate Aβ (101%±11.1% of controls, N=6, p=0.74) or of N100 to generate its cleavage product (recognized by Val1744 antibody only; 129.9%±27.4, N=5, p=0.11). A -secretase inhibitor, DAPT (12, 13) , was used as a control, and reduced cleavage of both C100 and N100 substrates (69.3%±2.3% and 38.2%±16% of controls respectively; Fig. 5A and B, lane 4) . It should also be noted that there was no change in levels of -secretase/PS1 total proteins in APP/PS1 +/-synj1 +/-mouse brains (Fig. 3A) . Moreover, the levels of βCTF (precursor of Aβ) are not changed with synj1 knockdown in cells and in transgenic mouse brains ( Fig. 1 and 3) . These data altogether suggest that synj1 downregulation does not affect -secretase cleavage of APP to generate Aβ in our system.
Reduction of Synj1
Accelerates Aβ Uptake into the Cells-We then investigated the rate of cellular Aβ uptake with reduced synj1 expression. As shown in Figure 6A , the amount of biotin-Aβ 42 It has been reported that the majority of internalized Aβ traffics through Rab5-and Rab7-positive early and late endosomes, respectively. Most internalized Aβ is delivered to the lysosomal pathway for degradation (32 + recycling endosomes after 3 hours of incubation (data not shown), suggesting that the rate of Aβ recycling between endosomes and plasma membrane is not changed by syn1j reduction.
We next studied whether increased Aβ uptake with synj1 reduction is dependent upon elevated PIP 2 levels, using a pharmacological reagent m-3m3FBS that activates phospholipase C (PLC) to deplete PIP 2 inside the cells (11) . As shown in Fig. 6C , the amount of Aβ taken up by control cells was modestly decreased with reduction of PIP 2 (86.4±7.8%, p=0. 24 ). An inactive analog of m-3m3FBS was used as a control (o-3m3FBS). However, in synj1 knockdown cells, the amount of Aβ taken up by cells remained increased even with treatment to reduce PIP 2 (149.6±8.0% in m-3-FBS treated versus 144.3±24.3% in o-3-FBS treated conditions).
Together, our data suggests that reduction of synj1 accelerates Aβ uptake into cells and delivery to early endosomes. However, the increased Aβ uptake is independent from PIP 2 increase induced by synj1 reduction.
Reduction of Synj1 Increases Cellular Aβ
Degradation-The rate of Aβ turnover was next determined in N2a cells with synj1 siRNA transfection by cycloheximide (CHX) timecourse experiments (Fig. 7A) . Synj1 knockdown resulted in decreased cellular Aβ levels at time point 0 (59.7±13.9%; p=0.015), consistent with prior observations (Fig. 1A) . At 60 minutes of incubation, the amount of Aβ was diminished by 37.5% with synj1 knockdown (reduced to 22.2±12.1% of control levels at time point 0) whereas Aβ levels in controls were only reduced by 11.5% (88.5±15.2% of control levels at time point 0). However, synj1 reduction does not affect APP turnover rate. As shown in Fig. 7B , the amount of holoAPP in lysates was comparable between control and synj1 siRNA treated conditions at all time points (0-180 min) after exposure of cells to CHX.
These results in combination with previous data (Fig. 3 and 5) suggest that the reduced Aβ levels with synj1 down-regulation are likely due to accelerated degradation of Aβ instead of reduced generation.
Delivery of Internalized Aβ 42 to LAMP1 + Lysosomes Increases in Synj1
-/-Primary Neurons-We next investigated whether Aβ trafficking through the endosomal/lysosomal pathways was increased with synj1 reduction. Immunostaining with antibodies against LAMP1 was performed in mouse cultured cortical neurons after incubation with Alexa 555 -Aβ 42 (500 nM) for 24 hours. We found that Aβ 42 was colocalized with a lysosomal marker LAMP1 (Fig.  8 A and B, top panels) . However, the amount of Aβ 42 co-localized with LAMP1 + lysosomes, was significantly increased in both cell bodies and neurites of synj1 +/-and synj1 -/-neurons ( Fig. 8 A  and 
Reduction of Synj1 Increases
Aβ Degradation in Lysosomes Partially through Elevated PIP 2 Levels--Furthermore, to assess lysosomal degradation of Aβ, we tested the effects of lysosomal inhibitors (Leupeptin, Pepstatin A and E-64d), which block lysosomal enzyme activities (32, 33) . N2a cells transfected with synj1 or control siRNA for 4 days, were then incubated in the presence or absence of lysosomal inhibitors for 24 hours. The amount of media and cell-associated Aβ in the presence of lysosomal inhibitors, determined by IP/WB, were significantly increased ( Fig. 9A ; middle and right panels), indicating that lysosomal degradation of Aβ is a significant mechanism for elimination of Aβ following cellular Aβ uptake. More importantly, inhibition of Aβ degradation through lysosomal pathways abolishes the Aβ lowering effects of synj1 reduction (with lysosomal inhibitors, media Aβ 192.5±8.8% in controls versus 185.3±2.6% in synj1 siRNA; lysate Aβ 156.1±10.5% in controls versus 185.0±14.0% in synj1 siRNA).
The amount of Aβ degraded by lysosomes was determined by subtracting the mean values of Aβ in the absence of lysosomal inhibitors from the values in the presence of inhibitors. Synj1 reduction increases lysosomal degradation of cellular Aβ by 112.6±57.6% (p=0.021) and media Aβ by 30.6±17.5% (p=0.043) if compared to controls (Fig. 9B) . These data suggest that the Aβ-lowering effects of synj1 reduction are mainly mediated through promoting lysosomal degradation.
We next studied whether the increased Aβ degradation with synj1 reduction is dependent upon elevated PIP 2 levels, using synj1 knockdown N2a cells treated with a PIP 2 depleting reagent (m-3-FBS). As shown in Fig.  9C , the addition of m-3-FBS completely abolished the Aβ-lowering effects induced by synj1 reduction (109.4±13.6% in synj1 siRNA +m-3-FBS versus 94.6±6.5% in control siRNA+m-3-FBS). Moreover, the amount of Aβ accumulated in the presence of lysosomal inhibitors was not increased further by addition of a PIP2 depleting reagent (m-3-FBS/lyso inh. columns, 146.9±11.8% in lyso inhibitors alone versus 138.5±12.8% in m-3-FBS+lyso inhibitors), suggesting that the effects of PIP 2 on Aβ levels act through the same endosomal/lysosomal degradation pathway.
In summary, our data suggests that reduction of synj1 increases cellular Aβ uptake, endosomal/lysosomal trafficking and degradation, partially by increasing the levels of PIP 2 .
Discussion
Recent studies indicate that late-onset AD is likely caused by an overall impairment in Aβ clearance (6) . Furthermore, several studies report pathological changes of the lysosomal network, which develop in neurons as Alzheimer disease progresses, and include dysregulation of endocytosis and progressive failure of lysosomal clearance mechanisms (34) (35) (36) . A close connection between lysosomal protein clearance failure and mechanisms of neurodegeneration is also well documented (36) (37) (38) (39) .
In this study, we defined a novel mechanism by which a PI(4,5)P 2 degrading enzyme, synaptojanin 1 (synj1) regulates the cellular itinerary of Aβ. We show that down-regulation of synj1 in the brain, promotes Aβ uptake by neurons, accelerates Aβ delivery to the endosomal/lysosomal pathway, increases Aβ degradation, and thereby reduces amyloid plaque load and attenuates behavioral deficits in AD transgenic animals.
As proposed in our model (Fig. 10) , in wildtype (WT) cells, extracellular Aβ is internalized into the early endosomes, and either recycled back to the plasma membrane (PM) through recycling endosomes or delivered to late endosomes/lysosomes for degradation. Under synj1 knockdown (KD) conditions, extracellular Aβ is rapidly internalized to the early endosomes and delivered to the late endosomal/lysosomal pathway for degradation. However, the amount of Aβ generated by APP processing/cleavage, as well as the rate of cellular Aβ recycling from the early endosomes to the plasma membrane remain unchanged. As a consequence, Aβ is being more rapidly degraded while no more is being synthesized. The amount of extracellular and intracellular Aβ at steady state is subsequently decreased by synj1 KD.
Synj1 has been linked to AD and Down's syndrome (2, 3, 7) . It is a phosphatase that catalyses the dephosphorylation of the signaling phospholipid PI(4,5)P 2 which is shown to control clathrin-mediated endocytosis (40, 41) . Studies in the mouse and other model organisms have found that synj1 plays a critical role in synaptic vesicle recycling, actin regulation, as well as glutamate receptor trafficking (1, 42) . Intriguingly, our results suggest that reduction of synj1 can promote Aβ uptake and internalization through endosomal pathway (Fig. 6) , and these effects are independent upon PI(4,5)P 2 elevation (Fig. 6C) . It is unclear to us whether this synj1-enhanced internalization is specific to Aβ. Further characterization in these aspects is currently ongoing.
Interestingly, others reported that haploinsufficiency of synj1 protects against Aβ induced defects in long-term potentiation (3) and ameliorates learning and memory deficits in a transgenic mouse model of AD (2) . It was also suggested that increased PI(4,5)P 2 caused by down-regulation of synj1 suppresses Aβ oligomer induced neurotoxic effects (2,3,7). Our data suggest that the promotion of cellular Aβ degradation with synj1 reduction is partially dependent upon elevated PIP 2 levels because pharmacological reduction of PIP 2 abolishes the Aβ-lowering effects in synj1 knockdown conditions (Fig. 9C) . Together, these findings support the notion that elevation of PI(4,5)P 2 by synj1 reduction is neuroprotective against AD.
Our novel studies demonstrate that reduction of synj1 accelerates cellular Aβ uptake and delivery to lysosomes, and thereby promotes Aβ degradation and reduces amyloid plaque load in an AD transgenic mouse model. It should be noted that the reduction in amyloid plaque load is most prominent in hippocampus, which could contribute to functional rescue of learning and memory deficits in our AD transgenic mouse model (Fig. 4) and is consistent with others' observations (42) . The specific changes in hippocampal Aβ due to synj1 reduction likely indicate potential sensitivity of hippocampal neurons to down-regulation of synj1. However, we did not see any significant difference in plaque load in neocortical regions, possibly due to heavy plaque burden at this stage. In contrast, we did observe a robust reduction of intracellular Aβ within both cortical and hippocampal neurons at the pre-plaque stage of young Swedish APP/PS1E9 +/-synj1 +/-mice (data not shown), suggesting a potential therapeutic strategy targeting synj1 at early stages of AD.
It should be also noted that in McIntire et al.'s studies, no alterations in Aβ levels were evident in 6-month old Tg2576 mice with synj1 haploinsufficiency (2) despite the fact that they previously reported that Aβ biogenesis is modulated by PI(4,5)P 2 (11). They measured the whole brain lysates at 6 months of age, whereas we specifically quantified Aβ and amyloid plaque load from hippocampus in older mice (10 months of age). Moreover, our data suggest that the Aβ-lowering effects induced by synj1 downregulation are mainly dependent on the promotion of cellular Aβ degradation without affecting Aβ generation through cleavage of APP by β-and -secretase. There was no change in levels of -secretase/PS1 or BACE-1 total proteins in APP/PS1 +/-synj1 +/-mouse brains ( Fig. 3A and B) . Furthermore utilizing a wellestablished in vitro -secretase assay (25, 26) , we have found that synj1 knockdown did not affect -secretase cleavage of C100 to generate Aβ or N100 to generate its cleavage product (Fig. 5) .
On the other hand, we observed that synj1 reduction promotes α-secretase cleavage of APP and up-regulates expression levels of α-secretase ADAM10 (unpublished data/manuscript in preparation). Promoting APP processing through the non-amyloidogenic pathway by synj1 reduction can further strengthen rescue of AD related changes (43, 44) . For example, the α-secretase-derived soluble APP N-terminal fragment, sAPPα has been suggested to have neurotrophic and neuroprotective functions, further supporting the therapeutic value of reducing synj1 levels in the brain (45) . Although α-secretase competes with BACE for APP cleavage and has the capacity to pre-empt Aβ generation, it is unlikely that this is the main mechanism underlying synj1 KD induced Aβ lowering effects. Our data ( Fig. 1 and 3) show that the levels of βCTF, the immediate precursor of Aβ, are not affected by synj1 reduction suggesting that the BACE cleavage of APP is not affected under our conditions. More importantly, increased synj1 expression has been functionally linked to the enlargement of early endosomes (46) . It has been reported that endosome anomalies are the earliest specific pathology reported in AD brain tissue (47,48). We here show that synj1 regulates endosomal trafficking and lysosomal degradation of Aβ. Reduction of synj1 can promote intracellular Aβ degradation through the endosomal/lysosomal pathway. Therefore, it would be interesting to investigate whether synj1 reduction can reverse early AD pathological changes such as enlargement of early endosomes.
In summary, our studies demonstrate a novel mechanism by which a PI(4,5)P 2 degrading enzyme, synaptojanin 1 (synj1) regulates the cellular itinerary of Aβ. We show for the first time that endosomal/lysosomal degradation of Aβ can be modulated by phosphoinositol homeostasis. Importantly, endosomal anomalies are considered as one of the earliest AD pathology and increased function of synj1 is linked to enlargement of early endosomes. Thus, our findings uncover a new therapeutic direction for AD aiming at modulation of cellular Aβ clearance by a phosphoinositol regulator, in the hopes of reversing amyloid induced pathological changes and cognitive deficits. Swedish mutant APP cells were treated with synj1 or control siRNA duplex for 4-5 days before analysis. Levels of media and intracellular Aβ, as well as βCTF were analyzed by immunoprecipitation with 4G8 followed by immunoblotting with 6E10. Levels of synj1 and β-actin were detected from cell lysates. Treatment with DAPT was included as a control. B) Protein levels were normalized to actin and expressed as percentage of control. Data were collected in duplicate or triplicate from three independent experiments. Significant reductions (**p<0.001) of Aβ in media and lysate and reduction of synj1 protein levels were observed upon synj1 knockdown, as compared to control. Levels of Aβ 40 and Aβ 42 in the media were determined by sandwich ELISA analysis (**p<0.001). In wildtype (WT) cells, secreted Aβ is internalized into early endosomes, followed by either recycling back to plasma membrane through recycling endosomes or delivered to late endosomes/lysosomes for degradation. With synj1 knockdown (KD), Aβ is more rapidly internalized to the early endosomes and delivered to the late endosomal/lysosomal pathway for degradation. As a consequence, the amount of secreted and cellular Aβ is decreased with synj1 reduction. The increased Aβ uptake and internalization to early endosomes with synj1 reduction are independent upon elevated PIP 2 , whereas the effects of accelerated Aβ degradation in lysosomes by synj1 reduction are PIP 2 dependent.
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